Search Results
Your search for ,ITS matches 8694 pages
Showing 4251 - 4300Blinatumomab in Adult and Pediatric Patients With B-Cell Precursor Acute Lymphoblastic Leukemia
EARLY IN 2018, blinatumomab (Blincyto) was granted accelerated approval for the treatment of adult and pediatric patients with B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease ≥ 0.1%.1,2 Supporting Efficacy Data APPROVAL WAS...
Psycho-oncology: After Decades of Acceptance, Still an Emerging Field
As the field of psycho-oncology continues to mature, new studies are being conducted to evaluate ways to better address the needs of patients with cancer and their families. The ASCO Post recently spoke with Michael Hoerger, PhD, MSCR, Assistant Professor of Psychology, Psychiatry, and Oncology at ...
SMARTIE Initiative for Advanced Practitioners in Oncology Recognized by Alliance for Continuing Education
AN ONGOING educational initiative, the Study to Measure Advanced Practitioner Retention of Targeted Information and Education (SMARTIE), measures oncology learning and how it is used with advanced practitioners and their patients with cancer. The initiative, conducted by Harborside Medical...
2019 Pershing Square Sohn Cancer Research Prize Is Opening for Applications on October 1, 2018
The Pershing Square Sohn Cancer Research Alliance will open for applications for its 2019 Pershing Square Sohn Prize for Young Investigators in Cancer Research on October 1, 2018. At least 6 New York City area–based scientists will each be awarded $200,000 per year for up to 3...
Outcomes for Rural Patients With Cancer Enrolled in Clinical Trials
The disparity in survival rates between rural and urban patients is reduced when patients in both settings are enrolled in clinical trials, SWOG study results show. The study results were published in JAMA Network Open by a team led by Joseph Unger, PhD, a SWOG biostatistician...
Active Surveillance of Lung Subsolid Nodules May Reduce Unnecessary Surgery and Overtreatment
Subsolid nodules can be considered a biomarker of lung cancer risk, and should be managed with long-term active surveillance. Conservative management of these nodules may reduce unnecessary surgery and overtreatment in patients with multiple comorbidities and aggressive lung cancer arising from...
FDA Accepts Biologics License Application, Grants Priority Review for Tagraxofusp in Rare Hematologic Malignancy
The U.S. Food and Drug Administration (FDA) has accepted for filing a biologics license application (BLA) for tagraxofusp (Elzonris, formerly SL-401) for the treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematologic malignancy. The FDA also granted Priority ...
A New Way to Contribute to Research: Join ASCO’s Research Survey Pool
Researchers frequently contact ASCO with requests to survey Society members. To help facilitate this type of research for ASCO members, ASCO has changed its previous policy of declining such requests and is now assembling a cohort of members who are willing to participate in investigator-initiated...
2019 Physician Fee Schedule and Quality Payment Program Proposed Rules Released
The Centers for Medicare & Medicaid Services (CMS) released its proposed rule for 2019 Medicare physician reimbursement. CMS estimates that in 2019, the overall impact for the hematology/oncology specialty will be a 4% reduction in reimbursement and a 2% reimbursement reduction for...
Daratumumab in Newly Diagnosed Transplant-Ineligible Multiple Myeloma
In May 2018, daratumumab (Darzalex) was approved for use in combination with VMP (bortezomib, melphalan, and prednisone) in the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.1 Supporting Efficacy Data Approval was based on...
AACR Appoints New Editors-in-Chief of Cancer Prevention Research
The American Association for Cancer Research (AACR) has announced the appointments of Raymond N. DuBois, MD, PhD, and Michael N. Pollak, MD, as Editors-in-Chief of Cancer Prevention Research, one of eight journals published by the AACR. Cancer Prevention Research publishes original preclinical,...
Obesity and Cancer: Complex Interplay of Multiple Factors
The evolving concept that dietary fat plays an important role in the etiology of human cancer emerged more than 50 years ago. Ernst Wynder, MD, whose seminal epidemiologic work led to identifying smoking as a contributory cause of lung cancer, presented a paper in 1967 showing a decided correlation ...
Enzalutamide in Nonmetastatic Castration-Resistant Prostate Cancer
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On July 13, 2018, enzalutamide (Xtandi) was approved for...
University of Pittsburgh Medical Center to Assist Cancer Center in Beijing
To meet the growing demand for high-quality cancer care in China, Tahoe Hospital Management Co Ltd has reached a 5-year agreement with the University of Pittsburgh Medical Center (UPMC) where health-care professionals from the Pennsylvania-based medical center will assist in the planning and...
Navigating the ‘New Normal’: NCCN Summit Examines Access to High-Quality Cancer Care
It’s not just the leaps in development of precision medicines, the soaring costs, the new payment models, clinical trial designs, sources of data, and federal policies. It’s all of them plus the rapidity with which change is happening that makes this era of oncology exceptional. “I would say...
Cannabinoids for Cancer Pain: Dangerous or Beneficial?
Cannabis has been used in health care for millennia, and its use has been well documented, albeit never definitively integrated into clinical practice. Recent societal changes and the increasing acceptance and availability of cannabis have reignited the medical and public debate around its role in...
Therapeutic Applications for Cannabinoids in Oncology: The Debate Continues
In the early part of the 20th century, the U.S. government classified cannabis as a Schedule 1 drug: a dangerous substance with no medical value. For many years, that classification prevented systematic research in cannabinoid use in medicine. As a result of societal changes and an intense and...
Stakeholders Agree: ‘Value’ in Cancer Care Depends on Perspective
In a roundtable discussion moderated by Clifford Goodman, PhD, of The Lewin Group, Falls Church, Virginia, representatives of the patient advocacy community, public and private payers, large and small clinics, and the pharmaceutical industry did not always see eye to eye on what “value” means nor ...
Venetoclax and Beyond: Successfully Targeting BCL2
Although many agents have been able to successfully inhibit the proliferative capacity of cancer cells or disable mutations that spur cancer growth, one area that has proven elusive is the apoptotic pathway—the cell’s means of resisting death. That is until recently. Dysregulation of B-cell...
Medical Marijuana: Research Not Anecdotes
For patients with cancer, marijuana may be valuable in controlling pain and chemotherapy-induced nausea and vomiting. Furthermore, it may have efficacy as an appetite stimulant. No randomized clinical trial has investigated the utility of whole-plant medical marijuana to alleviate these symptoms in ...
Unraveling the Mystery of What Gives Exceptional Responders Their Superpower
Once dismissed as rare medical miracles that overcame overwhelming odds to thwart cancer, exceptional responders to cancer treatment are now the subject of intense study. In 2015, the National Cancer Institute (NCI) announced the launch of its Exceptional Responders Initiative, with the goal of...
For Hodgkin Lymphoma, PD-1 Blockade Is Not the Final Answer
Although programmed cell death protein 1 (PD-1) blockade is highly effective in Hodgkin lymphoma, not all patients respond, and not all responses are durable. Stephen M. Ansell, MD, PhD, Chair of the Mayo Clinic Lymphoma Group and Professor of Medicine at the Mayo Clinic, Rochester, described...
VB4-845 Granted Fast Track Designation by FDA for Treatment of Non–Muscle Invasive Bladder Cancer
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VB4-845 for the treatment of bacillus Calmette-Guérin (BCG)–unresponsive, high-grade, non–muscle invasive bladder cancer. VB4-845 is currently being evaluated in a phase III registration...
FDA Grants Clearance of PowerLook Density Assessment for Digital Breast Tomosynthesis
iCAD has announced U.S. Food and Drug Administration (FDA) clearance of its artificial intelligence software program, PowerLook Density Assessment Version 3.4, which provides an automated method of determining breast density. The software is compatible with iCAD’s digital breast...
Cory Wiegert Named New CEO of CancerLinQ LLC
Cory Wiegert has been named Chief Executive Officer (CEO) of CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO. Mr. Wiegert, a proven expert in building and successfully launching innovative technology solutions, began his new role today (August 13, 2018), overseeing the continued...
Assay Uses Big Data to Predict Responses to Immunotherapy
In the age of big data, cancer researchers are discovering new ways to monitor the effectiveness of immunotherapy treatments. Researchers at the Johns Hopkins Bloomberg~Kimmel Institute for Cancer Immunotherapy developed a new way to use bioinformatics as a gathering tool to determine how ...
FDA Grants 510(k) Clearance to SRT-100+ Superficial Radiation Therapy for Treating Nonmelanoma Skin Cancer and Keloids
Sensus Healthcare, Inc, a medical device company specializing in the noninvasive treatment of nonmelanoma skin cancers and keloids with image-guided superficial radiation therapy, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its new...
Why Do You Live to Conquer Cancer? Join New ASCO Campaign to Share Your Story!
ASCO RECENTLY launched its new “I Live to Conquer Cancer” national outreach and awareness campaign to draw attention to the critical importance of federally funded cancer research. Through a series of compelling videos and written stories, “I Live to Conquer Cancer” puts a human face on cancer...
AMA House of Delegates Adopt ASCO Resolutions
ASCO DELEGATES participated in the American Medical Association’s (AMA) June Annual Meeting of the House of Delegates (HOD). The AMA HOD is the principal policy-making body of AMA and meets twice a year to discuss pressing issues and establish association policies. This year, delegates approved...
CMS Proposes Extended 340B Cuts for 2019
ON JULY 25, the Centers for Medicare & Medicaid Services (CMS) released its 2019 Hospital Outpatient Prospective Payment System proposed rule. Among other provisions, the proposal would extend 2018 reimbursement cuts to the 340B Drug Pricing Program to include currently excepted, off-site...
TAILORx: How to Apply This Landmark Study
TAILORx changes the configuration of the ball field and the shape of the ball in deciding which women will be recommended chemotherapy after resection of node-negative, hormone receptor–positive breast cancer. TAILORx was presented by Joseph Sparano, MD, at the 2018 ASCO Plenary Session and...
FDA Approves HPV Test for First-Line Cervical Cancer Screening
ON JULY 30, 2018, Roche announced approval by the U.S. Food and Drug Administration (FDA) of its cobas HPV Test in first-line screening for cervical cancer in women 25 years and older using cervical specimens collected in SurePath preservative fluid. The FDA first approved the cobas HPV test...
Meeting the Challenges of Immunotherapy-Related Toxicities
In 2011, the U.S. Food and Drug Administration (FDA) approved ipilimumab (Yervoy), an anticytotoxic T-lymphocyte– associated antigen 4 (CTLA-4), the first checkpoint inhibitor for the treatment of advanced melanoma.1 Since then, several more checkpoint inhibitors directed at both the programmed...
Ensuring Quality With Patient-Reported Outcomes and Electronic Health Records
Accurately assessing the quality of cancer care over the continuum of treatment requires a special set of metrics and data-gathering methods. Moreover, with a growing number of cancer survivors, the post-treatment care involves primary care providers who are adept at managing the comorbidities...
Is Some DNA Worthless?
BOOKMARK Title: Junk DNA: A Journey Through the Dark Matter of the GenomeAuthor: Nessa CareyPublisher: Columbia University PressOriginal publication date: April 2015Price: $22.95, paperback, 360 pages When biologists first delved into the human wonder of genes in the 1970s, they eventually...
A Celebrity Gadfly’s Reflections on His Death and Other Things Meant to Irritate
BOOKMARK Title: MortalityAuthor: Christopher HitchensPublisher: Twelve: Hachette Book GroupOriginal Publication Date: May 13, 2014Price: $19.95, paperback, 128 pages “There are no atheists in foxholes” is an aphorism used to contend that in times of extreme fear, such as during war or facing a...
Is Universal Health Care a Human Right?
The Affordable Care Act (ACA) provided oncology services to people with cancer who had previously been denied coverage. And for that reason alone, many oncologists supported its passage. However, even though the U.S. health-care system remains in the crosshairs of partisan politics, parties on both ...
ASCO and Friends Submit Recommendations to FDA Aimed at Reducing Barriers to Clinical Trial Participation
ASCO and Friends of Cancer Research (Friends) have submitted recommended language to the U.S. Food and Drug Administration (FDA) for five guidance documents on ways to broaden eligibility criteria for cancer clinical trials. The recommendations are part of an ASCO...
Guidelines for Pediatric CAR T-Cell Therapy Developed
Almost 1 year after the U.S. Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell therapy for children with acute lymphoblastic leukemia (ALL), researchers at The University of Texas MD Anderson Cancer Center and the Pediatric Acute Lung Injury and...
Reishi Mushroom
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. Ting Bao, MD, DABMA, MS, and Jyothirmai Gubili, MS, present information on the use of reishi...
Durvalumab After Chemoradiation in Unresectable Stage III NSCLC
Early in 2018, durvalumab (Imfinzi) was approved for the treatment of unresectable stage III non–small cell lung cancer (NSCLC) that has not progressed following concurrent platinum-based chemotherapy and radiation therapy.1,2 Supporting Efficacy Data Approval was based on a planned interim...
ACS Commission on Cancer Announces Outstanding Achievement Awards
The Commission on Cancer of the American College of Surgeons (ACS) has granted its 2017 Outstanding Achievement Award to a select group of 16 accredited cancer programs throughout the United States. Award criteria were based on qualitative and quantitative surveys of cancer programs conducted...
St. Baldrick’s Foundation Announces 2018 Summer Grant Recipients
The St. Baldrick’s Foundation has announced its 2018 summer grant recipients, including seven from Baylor College of Medicine and Texas Children’s Cancer and Hematology Centers. 2018 Recipients Nmazou Ozuah, MD, Assistant Professor of Pediatrics, received an international scholar grant for...
FDA Warns of Increased Risk of Cancer Relapse With Long-Term Use of Azithromycin After Allogeneic Stem Cell Transplant
The U.S. Food and Drug Administration (FDA) is warning that the antibiotic azithromycin should not be given on a long-term basis to prevent the inflammatory lung condition bronchiolitis obliterans syndrome in patients with cancers of the blood or lymph nodes who undergo a donor stem cell...
New Tool for Assessing Frailty in Patients With Newly Diagnosed Multiple Myeloma
A NEW “frailty index” may predict overall survival for patients newly diagnosed with multiple myeloma, according to a study published in JCO Clinical Cancer Informatics.1 Frailty is a critical factor in treatment decision-making for many patients with multiple myeloma, as many of these patients are ...
Lack of Congruence Among Tools Used to Assess Cancer-Related Cognitive Dysfunction
THE ASSESSMENT of cognitive dysfunction in patients who have undergone chemotherapy is complex, and although a number of strategies are available, each has its limitations, according to Karin Olson, RN, PhD, Professor in the Faculty of Nursing at the University of Alberta, Edmonton, Canada. At...
More Antibody-Drug Conjugates Expected to Impact Treatment of Lymphoma
FOR THE TREATMENT of lymphoma, antibody-drug conjugates (ADCs) are becoming an important class of drugs, as described at the 2018 Pan Pacific Lymphoma Conference by Brad Kahl, MD, Professor of Medicine at Washington University School of Medicine, St. Louis.1 “We have one ADC—brentuximab vedotin...
CAR T-Cell Therapy in Lymphoma: Challenges Come With Success
THE EMERGENCE of chimeric antigen receptor (CAR) T-cell therapy has sparked a wave of optimism in hematologic malignancies, but as experience in using CAR T-cell therapy has grown, new challenges have surfaced. A pioneer in the field, David G. Maloney, MD, PhD, enlightened attendees on these issues ...
New Frontiers Being Explored in Multiple Myeloma
BEFORE TOO LONG, oncologists can expect to have an entirely new arsenal in the fight against multiple myeloma. Cutting-edge therapies on the near horizon were described in a presentation by Kenneth Anderson, MD, at the 2018 American Association of Cancer Research’s (AACR’s) inaugural conference on...
The US Oncology Network Promotes Marcus Neubauer, MD, to Chief Medical Officer
THE US ONCOLOGY Network recently announced the appointment of Marcus Neubauer, MD, as Chief Medical Officer, building on its mission of delivering a comprehensive approach to cancer care. Michael Seiden, MD, PhD, will continue to lead The US Oncology Network as its President. Dr. Neubauer has...
